SS-31 Is Making Me Tired, Not Energetic. Is That Normal?

Where does the "repair stage" explanation come from?

Partly from real research, and the part that matters is not.

The mechanism has research behind it. Cardiolipin is not only a structural lipid. When it moves from the inner mitochondrial membrane to the outer surface, it acts as a signal that marks a damaged mitochondrion for disposal, a process called mitophagy. And SS-31 does appear to act on that system: in a mouse model of Barth syndrome, treatment improved defective mitophagy in heart tissue and reduced a marker that accumulates when the process is blocked.⁵

So "SS-31 is involved in clearing damaged mitochondria" is not something a forum invented. It is a real finding, in mice, in a disease model, measured as protein markers in heart tissue.

What gets added to it has nothing behind it. We could not find a study describing that process having a felt metabolic cost, a trial measuring an early fatigue phase followed by improvement, or a paper proposing that a person undergoing mitophagy would feel tired and then stop feeling tired when it finished.

That is the leap: from protein markers in a mouse heart to how you feel in week three. The mechanism is cited. The feeling is assumed. And the assumption is what people are being told to push through on.

It is also the part that would be testable and has not been tested. A trial could look at whether fatigue early in treatment predicts a later response. MMPOWER-3 ran for 24 weeks in 218 people and would have been the obvious place to find such a pattern. It is not reported.

Our guide on why most peptides have no human evidence covers this shape, where a genuine mechanism at one level of detail gets extended into a felt experience at another, and only the mechanism carries a citation.

Is fatigue a known side effect of SS-31?

It is in the trial records, though it is not among the listed side effects on the label.

In the trial data. The open-label extension of the primary mitochondrial myopathy programme recorded fatigue in 6 of 28 participants, 21.4%.¹ Fatigue and asthenia also appear among the adverse event terms collected in the larger phase 3 trial.⁴

On the label. Forzinity, the approved product, lists injection site reactions as the common adverse reactions: erythema in 100% of treated patients against 25% on placebo, pain in 75% against 42%, induration and pruritus each in 67% against 17%.³ Fatigue is not among them.

That gap is worth understanding rather than treating as a contradiction. The approval trial was tiny, ten patients completed the randomised portion, in a rare genetic disease. A small trial in a specific population will not surface everything a larger programme collects.

Can the trial fatigue numbers be applied to you?

Not cleanly. A confound sits in the middle of this and most coverage ignores it.

Every trial that collected fatigue data on this compound ran in people with mitochondrial disease, where fatigue is a core symptom of the condition being treated. So a participant reporting fatigue might be reporting their disease, the drug, or both, and the trial cannot separate them.

That cuts in an unexpected direction. It means the 21.4% figure is not transferable to a healthy person buying this for energy, and it also means nobody has collected fatigue data in anyone resembling the people in those threads.

Did any trial test whether SS-31 helps fatigue?

Yes. This is the part the threads never mention.

MMPOWER-3 randomised 218 adults with primary mitochondrial myopathy to elamipretide 40 mg daily or placebo for 24 weeks, with a total fatigue score as one of two co-primary endpoints. It was not met: a difference of -0.07 points at p = 0.37. The published paper states this provides Class I evidence that elamipretide does not improve the six-minute walk test or fatigue at 24 weeks in this population.²

Our compound page for SS-31 carries both endpoints in full, with the confidence intervals and the genotype analysis.

Two things make that harder to dismiss. The earlier phase 2 trial had found fatigue improved on the same scale, by 1.7 units at p = 0.0006, which is why the phase 3 was run. And the post hoc analysis that found a walking signal in one genetic subgroup did nothing for the fatigue result.

A positive phase 2 followed by a negative phase 3 is the most common shape in drug development. It is also the shape most likely to leave a compound with an energising reputation the larger trial did not support.

Does the trial dose match what people actually take?

No, and it is not close. Read the trial result against this before taking it as being about you.

MMPOWER-3 used 40 mg daily, subcutaneously, for 24 weeks. The doses people report buying and using run roughly 2 to 5 mg daily, with the wider range of reports spanning about 1 to 10 mg.⁶

So a person taking 3 mg is on something close to a tenth of the dose that did not improve fatigue at full strength.

That cuts in two directions and both are worth holding.

It limits what the trial tells you. A negative result at 40 mg does not establish what happens at 3 mg, in a different population, for a different reason. Nobody has tested that.

It also undercuts the energising reputation further. If 40 mg did not beat placebo on fatigue over 24 weeks in people whose disease causes fatigue, there is no basis for expecting a tenth of that dose to do more in someone without the disease.

Neither figure is a recommendation. The 40 mg is the trial and prescription dose for a rare genetic condition, and the 2 to 5 mg is what people report, which is a different kind of number entirely.

How long does SS-31 stay in your body?

The label does not say, which is itself a detail these threads have not looked at.

The Forzinity label states no half-life at all. What it does report is a time to peak concentration of 0.5 to 1 hour, bioavailability of 92%, and near-complete recovery in urine by 48 hours.³

Those figures point to a compound that arrives fast and is largely cleared within about two days. That is an inference from the elimination data rather than a stated half-life, and it is worth saying so, because the 2 to 3 hour figure circulating online does not come from the label either.

The threads describe something different: tiredness that builds over weeks and is attributed to an ongoing repair process. A drug largely eliminated within 48 hours has no obvious route to an effect that accumulates over weeks, and we could not find a study proposing one.

This does not prove the tiredness is unrelated to the injection. It does mean the story being told about it, that something is building up and being worked through, has the pharmacokinetics against it as well as the trial result.

So why are you tired?

Four possibilities. None has been studied in someone like you.

Something unrelated. Fatigue is among the most common symptoms in the general population and has a long list of ordinary causes, several of them testable. Our bloodwork guide covers which ones are worth checking, and iron, thyroid and B12 are the usual first three.

The injection itself. Injection site reactions are overwhelmingly the most common effect of this drug, and reactions that are itchy, painful and recurring disturb sleep and are tiring in their own right.

A direct effect that has never been characterised. Possible. Fatigue appears in the adverse event tables, which is weak evidence that something real is being captured, and the confound above means it cannot be read cleanly.

Expectation. You bought a compound for energy and are monitoring yourself for energy. People notice what they are looking for, in both directions.

Does any of this apply to a research vial?

Less than you would hope. The usual gap, wider here than for most compounds.

Everything above comes from trials of pharmaceutical elamipretide at a known dose in a supervised setting, in people with a rare genetic disease. None of it describes a research-labelled vial taken by a healthy adult for energy.

SS-31 is also among the more expensive compounds in this market, and our compound page tracks it across dozens of sellers with a wide spread in price per milligram. A high price is not evidence of anything, in either direction.

The approved indication is Barth syndrome, to improve muscle strength. Energy and fatigue in healthy people is not what it was approved for and not what it has been shown to do. Our MOTS-c comparison sets the two mitochondrial compounds side by side, since people often weigh them against each other.

When to stop and be seen

Tiredness is easy to explain away. That is why this list matters.

Breathlessness on exertion that is new, or a racing heart at rest.

Fatigue that keeps worsening rather than fluctuating, or that does not lift at all over several weeks.

Any injection site reaction that spreads, blisters, or comes with fever, and any hives away from the site, facial swelling or difficulty breathing. The label carries a hypersensitivity warning and reports that reactions have occurred from minutes to months after starting.³

And exhaustion that is stopping you doing ordinary things is a reason for a blood test rather than another month of assuming it is the repair stage.

Common questions

Is it normal to feel tired on SS-31?

Tiredness is reported often enough to fill threads, and nobody has studied it in people taking SS-31 for energy. Fatigue appears in the elamipretide trial records, including 21.4% in one open-label extension, and the phase 3 trial that measured fatigue as a formal endpoint found no improvement against placebo.

Is the fatigue part of a repair stage?

Part of that explanation is sourced and part is not. SS-31 does appear to act on mitophagy, the process that clears damaged mitochondria, in a mouse model of Barth syndrome. What has never been studied is whether that process causes tiredness in a person, or whether early fatigue predicts a later benefit.

Does the fatigue go away?

No answer has been published. The trials that collected fatigue data ran in people with mitochondrial disease, where fatigue is a symptom of the condition, so the data cannot be read as a timeline for anyone else.

Is fatigue a listed side effect of Forzinity?

No. The label lists injection site reactions as the common adverse reactions, with erythema in 100% of treated patients against 25% on placebo. Fatigue appears in trial adverse event tables but not on the label.

Did SS-31 fail a fatigue trial?

Yes. MMPOWER-3 used a total fatigue score as one of two co-primary endpoints in 218 adults, and did not meet it: a difference of -0.07 points at p = 0.37. The paper describes this as Class I evidence that the drug does not improve fatigue at 24 weeks in that population.

Does the trial dose match what people take?

No. MMPOWER-3 used 40 mg daily and community reports run about 2 to 5 mg. So the negative fatigue result came from roughly ten times the dose most people use, which limits what it tells you about a research vial and also removes any basis for expecting more benefit at a smaller dose.

How long does SS-31 stay in the body?

The label gives no half-life. It reports peak concentration within 0.5 to 1 hour and near-complete recovery in urine by 48 hours, which points to a compound largely cleared within about two days. That is an inference from the elimination figures, not a stated half-life. That does not fit a tiredness that builds over weeks.

Should I push through it?

That advice comes from the same threads as the unsourced explanation. If the tiredness is from something unrelated and testable, pushing through delays finding it.

What are the side effects of SS-31?

On the approved label, injection site reactions dominate: erythema in 100% of treated patients against 25% on placebo, pain in 75% against 42%. Fatigue appears in the trial adverse event tables, including 21.4% in one open-label extension, but is not among the label's listed adverse reactions.

What is SS-31 actually approved for?

Barth syndrome, a rare genetic mitochondrial condition, to improve muscle strength in patients weighing at least 30 kg. It received accelerated approval, which means confirmatory data is still required.

Could the tiredness be something else?

Yes, and that is the most useful thing on this page. Iron, thyroid and B12 are ordinary causes with ordinary tests, and recurring injection site reactions disturb sleep in their own right.

Sources

1. Open-Label Extension Trial to Characterize the Long-term Safety and Tolerability of Elamipretide in Subjects With Genetically Confirmed Primary Mitochondrial Myopathy. NCT02976038, posted results. clinicaltrials.gov. Open-label extension, 28 participants. Fatigue recorded in 6 of 28 participants, 21.4%, among other adverse events under general disorders. Injection site pruritus 64.3%, injection site mass and urticaria 46.4% each, injection site pain 35.7%, chest pain 21.4%. Participants had primary mitochondrial myopathy, in which fatigue is a symptom of the underlying condition.
2. Karaa A, Bertini E, Carelli V, Cohen BH, Enns GM, Falk MJ, et al. Efficacy and Safety of Elamipretide in Individuals With Primary Mitochondrial Myopathy: The MMPOWER-3 Randomized Clinical Trial. Neurology 2023. doi:10.1212/WNL.0000000000207402. NCT03323749. Phase 3, randomised, double-blind, placebo-controlled, 218 adults, 109 per arm, elamipretide 40 mg daily subcutaneously for 24 weeks. Co-primary endpoints were distance on the six-minute walk test and the Primary Mitochondrial Myopathy Symptom Assessment total fatigue score. Neither was met: total fatigue score difference -0.07 (95% CI -0.10 to 0.26, p = 0.37); 6MWT -3.2 metres (95% CI -18.7 to 12.3, p = 0.69). The paper states the study provides Class I evidence that elamipretide does not improve the six-minute walk test or fatigue at 24 weeks compared with placebo in this population. An earlier phase 2 trial had found fatigue improved on the same instrument by 1.7 units at p = 0.0006. A post hoc genetic subgroup analysis found improvement on the walking endpoint in participants with nuclear DNA variants and no differential effect on fatigue.
3. Forzinity (elamipretide) prescribing information. accessdata.fda.gov. The approved label. Describes elamipretide as a mitochondrial cardiolipin binder that localises to the inner mitochondrial membrane. Approved under accelerated approval to improve muscle strength in adult and paediatric patients with Barth syndrome weighing at least 30 kg. Adverse reactions occurring more commonly than on placebo are injection site reactions: erythema 100% against 25%, pain 75% against 42%, induration 67% against 17%, pruritus 67% against 17%, bruising 25% against 0%, urticaria 25% against 0%. Ten patients completed the randomised trial. Carries a hypersensitivity warning, noting reactions occurring from minutes to months after initiation. Fatigue is not among the listed adverse reactions.
4. A Trial to Evaluate Safety and Efficacy of Elamipretide in Primary Mitochondrial Myopathy Followed by Open-Label Extension. NCT03323749, posted results. clinicaltrials.gov. Trial record for MMPOWER-3. Fatigue and asthenia appear among the adverse event terms collected under general disorders. Injection site erythema 86.2% against 28.4% on placebo in the double-blind period, injection site pruritus 75.2% against 9.2%, injection site pain 39.5% against 18.4%.
5. Pennisi EM, et al. SS-31 treatment ameliorates cardiac mitochondrial morphology and defective mitophagy in a murine model of Barth syndrome. Scientific Reports 2024. doi:10.1038/s41598-024-64368-y. Animal study in doxycycline-inducible tafazzin knockdown mice. Reports that in vivo SS-31 treatment restored mitochondrial morphology in tafazzin-deficient heart by acting on proteins involved in mitochondrial dynamics and mitophagy, and significantly decreased SQSTM1/p62, indicating partial restoration of mitophagy. Notes that externalisation of cardiolipin from the inner to the outer mitochondrial membrane is a signal directing damaged mitochondria to mitophagy. This is a mouse disease model measuring protein markers in heart tissue; it does not measure fatigue, energy or any felt experience, and no study links this process to tiredness in a person.
6. Peptide Decoding compound record for SS-31 (elamipretide). peptidedecoding.com/peptides/ss-31. Our own data. Records two separate dose contexts: a community-reported range of 2 to 5 mg daily for research vials, with reports spanning roughly 1 to 10 mg daily, and 40 mg daily for the approved Forzinity product in eligible Barth syndrome patients. The page states that there is no established dose for general mitochondrial support or longevity. Community practice figures come from forums and social posts, not trials.

Citing this page. Peptide Decoding. SS-31 Is Making Me Tired, Not Energetic. Is That Normal? Trial figures as cited. https://peptidedecoding.com/guides/ss31-fatigue